The pharmacological management of Lennox-Gastaut syndrome and critical literature review.

Lennox-Gastaut syndrome (LGS) is a severe epileptic encephalopathy with a prevalence of 1-2% of all patients with epilepsy. It is characterized by multiple pharmaco-resistant seizure types, including tonic, atypical absences and tonic or atonic drop attacks, and the presence of electroencephalographic abnormalities, such as slow-spike waves and paroxysmal fast rhythms. Intellectual disability, behavioural and psychiatric disorders are common comorbidities; these disturbances have a multi-factorial pathogenesis. The selection of the most appropriate drug must be tailored to each patient and guided by the prevalent seizure type. In this paper available pharmacological options are discussed and for each pharmacological agent, current evidence of efficacy and tolerability is provided. Valproic acid represents one of the first-line options in the treatment of LGS. Anyway, other antiepileptic drugs (AEDs) may be considered and added: lamotrigine, rufinamide, topiramate, clobazam can be efficacious. The use of felbamate must be carefully evaluated because of its adverse events. Perampanel, zonisamide, levetiracetam and fenfluramine have shown to be useful in the treatment of selected patients; nevertheless, the lack of RCTs does not allow to recommend their use in a systematic way. Recently, cannabidiol has provided high evidence of efficacy against LGS seizures; however, these data must be confirmed by long-term extensive studies and by trials comparing different AEDs, one to each other.

• Publication year

  2018

• Venue

  Seizure

• Publication date

  2018-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.seizure.2018.10.016PMID 30391662
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Individualized treatment approaches: Fenfluramine, a novel antiepileptic medication for the treatment of seizures in Dravet syndrome.

  2019cited by this paper
• PharmGKB summary: clobazam pathway, pharmacokinetics

  2018cited by this paper
• Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results

  2018cited by this paper
• Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome

  2018cited by this paper
• Optimizing clobazam treatment in patients with Lennox-Gastaut syndrome.

  2018cited by this paper
• Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.

  2018cited by this paper
• Lennox-Gastaut syndrome: a comprehensive review

  2018cited by this paper
• PharmGKB summary: clozapine pathway, pharmacokinetics

  2018cited by this paper
• A pilot, open‐label study of the effectiveness and tolerability of low‐dose ZX008 (fenfluramine HCl) in Lennox‐Gastaut syndrome

  2018cited by this paper
• Use of perampanel in children and adolescents with Lennox-Gastaut Syndrome.

  2017cited by this paper
• Understanding Lennox–Gastaut syndrome: insights from focal epilepsy patients with Lennox–Gastaut features

  2017cited by this paper
• Lennox–Gastaut Syndrome: A Prospective Follow-up Study

  2017cited by this paper
• Expert Opinion on the Management of Lennox–Gastaut Syndrome: Treatment Algorithms and Practical Considerations

  2017cited by this paper
• Atlas of Electroencephalography, 3rd Edition.

  2017cited by this paper
• Lennox-Gastaut syndrome in adulthood: Long-term clinical follow-up of 38 patients and analysis of their recorded seizures.

  2017cited by this paper
• The role of EEG in the diagnosis and classification of the epilepsy syndromes: a tool for clinical practice by the ILAE Neurophysiology Task Force (Part 2).

  2017cited by this paper
• Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?

  2017cited by this paper
• Real-world data on rufinamide treatment in patients with Lennox-Gastaut syndrome: Results from a European noninterventional registry study.

  2017cited by this paper
• Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trial.

  2016cited by this paper
• Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study.

  2016cited by this paper
• Low‐dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients

  2016cited by this paper
• Deconstructing tolerance with clobazam

  2016cited by this paper
• Practice Update: Review of Anticonvulsant Therapy

  2016cited by this paper
• Five‐year extended follow‐up status of 10 patients with Dravet syndrome treated with fenfluramine

  2016cited by this paper
• Psychiatric and Behavioural Disorders in Children with Epilepsy (ILAE Task Force Report): Behavioural and psychiatric disorders associated with childhood epilepsy syndromes.

  2016cited by this paper
• Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug.

  2016cited by this paper
• Effectiveness and Tolerability of Perampanel in Children and Adolescents with Refractory Epilepsies: First Experiences

  2015cited by this paper
• Efficacy and tolerability of the ketogenic diet in Dravet syndrome - Comparison with various standard antiepileptic drug regimen.

  2015cited by this paper
• Safety of lamotrigine in paediatrics: a systematic review

  2015cited by this paper
• Rufinamide add-on therapy for refractory epilepsy.

  2015cited by this paper
• Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan.

  2014cited by this paper
• Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines.

  2014cited by this paper
• Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years

  2014cited by this paper
• Adjunctive levetiracetam treatment in pediatric Lennox-Gastaut syndrome.

  2014cited by this paper
• Efficacy and safety of rufinamide in children under four years of age with drug-resistant epilepsies.

  2014cited by this paper
• Lennox‐Gastaut syndrome: A consensus approach to differential diagnosis

  2014cited by this paper
• Mechanisms of Levetiracetam in the Control of Status Epilepticus and Epilepsy

  2014cited by this paper
• Networks underlying paroxysmal fast activity and slow spike and wave in Lennox-Gastaut syndrome

  2013cited by this paper
• Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes

  2013cited by this paper
• Clobazam

  2013cited by this paper
• Effectiveness and tolerability of rufinamide in children and young adults with Lennox-Gastaut syndrome: a single center study in Korea.

  2013cited by this paper
• Treatment of Lennox-Gastaut syndrome.

  2013cited by this paper
• De novo mutations in the classic epileptic encephalopathies

  2013cited by this paper
• Successful use of fenfluramine as an add‐on treatment for Dravet syndrome

  2012cited by this paper
• Rufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome.

  2012cited by this paper
• All children who experience epileptic falls do not necessarily have Lennox-Gastaut syndrome... but many do.

  2011cited by this paper
• Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome

  2011cited by this paper
• Definition and natural history of Lennox‐Gastaut syndrome

  2011cited by this paper
• An atypical case of Lennox-Gastaut syndrome not associated with mental retardation: a nosological issue.

  2011cited by this paper
• Low long-term efficacy and tolerability of add-on rufinamide in patients with Dravet syndrome.

  2011cited by this paper
• A systematic review of safety monitoring and drug toxicity in published randomised controlled trials of antiepileptic drugs in children over a 10-year period

  2010cited by this paper
• Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience.

  2010cited by this paper
• The evolution of antiepileptic drug development and regulation

  2010cited by this paper
• Adjunctive rufinamide in Lennox‐Gastaut syndrome: a long‐term, open‐label extension study

  2010cited by this paper
• Medical management of Lennox-Gastaut syndrome

  2010cited by this paper
• Lennox‐Gastaut syndrome with late‐onset and prominent reflex seizures in trisomy 21 patients

  2009cited by this paper
• Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology.

  2009cited by this paper
• Clobazam in the treatment of Lennox‐Gastaut syndrome

  2009cited by this paper
• Discovery and development of lamotrigine for bipolar disorder: a story of serendipity, clinical observations, risk taking, and persistence.

  2008cited by this paper
• Clinical efficacy of zonisamide in Lennox-Gastaut syndrome: Korean multicentric experience.

  2008cited by this paper
• Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome

  2008cited by this paper
• Treatment of pediatric epilepsy: European expert opinion, 2007.

  2007cited by this paper
• Pharmacokinetics and Drug Interactions with Zonisamide

  2007cited by this paper
• The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.

  2007cited by this paper
• Valproate‐associated Coagulopathies Are Frequent and Variable in Children

  2006cited by this paper
• Predictors of Lamotrigine‐associated Rash

  2006cited by this paper
• Felbamate: consensus of current clinical experience.

  2006cited by this paper
• Treatment of Pediatric Epilepsy: Expert Opinion, 2005

  2005cited by this paper
• Carbamazepine aggravates absence seizures in GAERS rats by acting on the ventrobasalthalamus via a GABA-A mediated mechanism

  2005cited by this paper
• The Influence Of Rufinamide On Sodium Currents And Action Potential Firing In Rodent Neurons: 3.062

  2005cited by this paper
• Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy

  2004cited by this paper
• Treatment of Lennox-Gastaut syndrome.

  2003cited by this paper
• Lennox-Gastaut Syndrome (Childhood Epileptic Encephalopathy)

  2003cited by this paper
• Effects of Age and Polytherapy, Risk Factors of Valproic Acid (VPA) Hepatotoxicity, on the Excretion of Thiol Conjugates of (E)‐2,4‐diene VPA in People with Epilepsy Taking VPA

  2003cited by this paper
• Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial.

  2002cited by this paper
• Single-Dose Pharmacokinetics of Lamotrigine in Children: Influence of Age and Antiepileptic Comedication

  2001cited by this paper
• Eating Seizures in Lennox-Gastaut Syndrome

  2001cited by this paper
• Topiramate in the treatment of severe myoclonic epilepsy in infancy.

  2000cited by this paper
• Safety and Tolerability of Topiramate in Children

  2000cited by this paper
• Topiramate in Lennox–Gastaut Syndrome: Open‐Label Treatment of Patients Completing a Randomized Controlled Trial

  2000cited by this paper
• A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome

  1999cited by this paper
• The Efficacy of Lamotrigine in Children and Adolescents with Refractory Generalized Epilepsy: A Randomized, Double‐Blind, Crossover Study

  1998cited by this paper
• Lamotrigine and Seizure Aggravation in Severe Myoclonic Epilepsy

  1998cited by this paper
• Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group.

  1997cited by this paper
• Add-On Therapy of Fenfluramine in Intractable Self-Induced Epilepsy

  1996cited by this paper
• Felbamate in the Treatment of Lennox‐Gastaut Syndrome: Results of a 12‐Month Open‐Label Study Following a Randomized Clinical Trial

  1993cited by this paper
• Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome).

  1993cited by this paper
• The Lennox‐Gastaut Syndrome

  1993cited by this paper
• Sodium valproate acutely inhibits lamotrigine metabolism.

  1992cited by this paper
• Treatment of self-induced photosensitive epilepsy with fenfluramine.

  1985cited by this paper
• Sodium Valproate: Monotherapy and Polytherapy

  1982cited by this paper

• Short-term vigabatrin is safe and effective in Lennox-Gastaut syndrome.

  2026cites this paper
• Long term safety and efficacy of vigabatrin in Lennox-Gastuat syndrome: a long way to go.

  2026cites this paper
• Efficacy, safety and tolerability of adjunctive cenobamate in pediatric and adult patients with Lennox Gastaut Syndrome.

  2025cites this paper
• Comparative analysis of safety and efficacy between brand and generic lamotrigine products in the Saudi market

  2025cites this paper
• Comparative effectiveness of epilepsy surgery versus additional anti-seizure medications for Lennox–Gastaut syndrome: study protocol for a multicenter, mixed-methods study

  2025cites this paper
• Potential of cenobamate as a broad-spectrum antiseizure medication

  2025cites this paper
• Balance of efficacy, side effects, impact on quality of life and pharmacoeconomic parameters of аnticonvulsants of different generations

  2025cites this paper
• The potential of laminar functional MRI in refining the understanding of epilepsy in humans

  2025cites this paper
• Cannabidiol metabolism in vitro: the role of antiseizure medications and CYP2C19 genotypes

  2025cites this paper
• Unraveling the neuroprotective effect of perampanel and lacosamide combination in the corneal kindling model for epilepsy in mice

  2025cites this paper
• Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm.

  2025cites this paper
• Safety of Drugs Used in Difficult-to-Treat Epileptic Syndromes: A Disproportionality Analysis Using the Eudravigilance Database

  2025cites this paper
• Seizure classification using a multimodal seizure monitoring system (Nelli) in Dravet and Lennox–Gastaut syndromes: A non‐randomized, single‐center feasibility study

  2025cites this paper
• Disproportionality analysis of the safety profile of rufinamide in the real world: an evaluation of the FDA Adverse Event Reporting System database

  2024cites this paper
• Molecular Mechanisms Underlying the Generation of Absence Seizures: Identification of Potential Targets for Therapeutic Intervention

  2024cites this paper
• Safety of Valproic Acid in the Treatment of Children with Epilepsy

  2024cites this paper
• Long‐term outcomes and adaptive behavior in adult patients with Lennox–Gastaut syndrome

  2024cites this paper
• Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox–Gastaut syndrome in clinical practice

  2024influential citation
• The Current Role of Valproic Acid in the Treatment of Epilepsy: A Glimpse into the Present of an Old Ally

  2024cites this paper
• Optimal dose of fenfluramine in adjuvant treatment of drug-resistant epilepsy: evidence from randomized controlled trials

  2024cites this paper
• The future of medicine: Strategic insights into drug repurposing

  2024cites this paper
• Therapeutic efficacy of voltage-gated sodium channel inhibitors in epilepsy

  2023cites this paper
• Towards Novel Potential Molecular Targets for Antidepressant and Antipsychotic Pharmacotherapies

  2023cites this paper
• Adapted Evidence-Based Clinical Practice Guidelines for Diagnosis and Treatment of Epilepsies in Children: A Tertiary Children's Hospital Update.

  2023cites this paper
• Obsesif Kompulsif ve İlişkili Bozuklukların Tedavisinde Glutamaterjik Modülatörlerin Rolü

  2023cites this paper
• Felbamate urolithiasis

  2023cites this paper
• In vivo laser speckle contrast imaging of 4-aminopyridine- or pentylenetetrazole-induced seizures

  2023cites this paper
• Treatment of drop attacks: Anti-seizure drug choices of pediatric neurologists in Saudi Arabia

  2023cites this paper
• Learnings in developmental and epileptic encephalopathies: what do we know?

  2023cites this paper
• Understanding Lamotrigine’s Role in the CNS and Possible Future Evolution

  2023cites this paper
• Unraveling The Role of Chitosan for Nasal Drug Delivery Systems: A Review

  2023cites this paper
• Centromedian thalamic neuromodulation for the treatment of idiopathic generalized epilepsy

  2022cites this paper
• Ketamine and Lamotrigine Combination in Psychopharmacology: Systematic Review

  2022cites this paper
• Novel animal model of combined generalized and focal epilepsy

  2022cites this paper
• Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study

  2022cites this paper
• Transcriptome meta-analysis of valproic acid exposure in human embryonic stem cells.

  2022cites this paper
• An Italian consensus on the management of Lennox-Gastaut syndrome.

  2022cites this paper
• Perampanel as adjuvant treatment in epileptic encephalopathies: A multicenter study in routine clinical practice.

  2022cites this paper
• A Case of Lamotrigine-Induced Inflammatory Myositis

  2022cites this paper
• Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies

  2022cites this paper
• Management of Lennox-Gastaut syndrome with deep brain stimulation: A systematic literature review

  2022cites this paper
• Síndrome de Lennox Gastaut. Reporte de caso clínico y minirevisión

  2022cites this paper
• Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies

  2021cites this paper
• Guidelines for pharmacological treatment of epilepsy

  2021cites this paper
• Long-term medical and social outcomes of patients with Lennox-Gastaut syndrome.

  2021cites this paper
• Patient and Caregiver Health State Utilities in Lennox-Gastaut Syndrome and Dravet Syndrome.

  2021cites this paper
• Lennox Gastaut Syndrome with Bilateral Temporo-Parietal Encephalomalacia Cyst in a Child: The First Indonesian Report

  2021cites this paper
• Efficacy and safety of antiseizure medication for Lennox–Gastaut syndrome: a systematic review and network meta‐analysis

  2021cites this paper
• Drug treatment of epilepsy: From serendipitous discovery to evolutionary mechanisms.

  2021cites this paper
• Voltage gated sodium channel inhibitors as anticonvulsant drugs: A systematic review on recent developments and structure activity relationship studies.

  2021cites this paper
• Efficacy and safety of rufinamide as adjunctive therapy in patients with Lennox Gastaut syndrome: A systematic review and Meta-analysis.

  2021cites this paper
• The Pharmacoresistant Epilepsy: An Overview on Existant and New Emerging Therapies

  2021cites this paper
• The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond

  2021cites this paper
• Comorbidities in Dravet Syndrome and Lennox–Gastaut Syndrome

  2021cites this paper
• Prevalence, healthcare resource utilization and mortality of Lennox-Gastaut syndrome: retrospective linkage cohort study.

  2021cites this paper
• Rational Antiepileptic Treatment in Childhood

  2021cites this paper
• How Can an Na+ Channel Inhibitor Ameliorate Seizures in Lennox–Gastaut Syndrome?

  2021cites this paper
• The Recommendations for the Management of Chinese Children With Epilepsy During the COVID-19 Outbreak

  2020cites this paper
• Novel therapeutic options for Dravet and Lennox-Gastaut syndrome

  2020cites this paper
• Neue Arzneimittel 2019

  2020cites this paper
• An Open Retrospective Study of a Standardized Cannabidiol Based-Oil in Treatment-Resistant Epilepsy

  2020cites this paper
• Antiepileptic Drug Selection According to Seizure Type in Adult Patients with Epilepsy

  2020cites this paper
• Cognitive, adaptive, and behavioral effects of adjunctive rufinamide in Lennox-Gastaut syndrome: A prospective observational clinical study.

  2020cites this paper
• Fenfluramine for the Treatment of Dravet Syndrome and Lennox–Gastaut Syndrome

  2020cites this paper
• Emerging Use of Epidiolex (Cannabidiol) in Epilepsy.

  2020cites this paper
• Lamotrigine in the maintenance treatment of bipolar disorder.

  2020cites this paper
• A reappraisal of atypical absence seizures in children and adults: therapeutic implications

  2019cites this paper
• [Why the diagnosis of Lennox-Gastaut syndrome is a rare one?]

  2019cites this paper
• Biological bases for a possible effect of cannabidiol in Parkinson’s disease

  2019cites this paper